Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies

Palazestrant in combination with the CDK 4/6 inhibitors, ribociclib and palbociclib, demonstrated no significant drug-drug interaction, no dose-limiting toxicities and a tolerability profile...

Related Keywords

Hollywood ,California ,United States ,Massachusetts ,Cambridge ,Cambridgeshire ,United Kingdom ,Texas ,San Francisco ,San Antonio ,Nedlands ,Western Australia ,Australia ,Marlene Chan ,Seanp Bohen ,Geoffrey Mogilner ,Henryb Gonzalez Convention Center ,Company Investor Webcast ,Breast Cancer Research ,Curtin University ,Nasdaq ,Exchange Commission ,Olema Pharmaceuticals Inc ,Securities Exchange ,Poster Spotlight Session ,San Antonio Breast Cancer Symposium ,Convention Center ,Antonio Breast Cancer Symposium ,Chief Executive Officer ,Breast Clinical Trials Unit ,Hollywood Private Hospital ,Investor Webcast ,Securities Act ,Securities Exchange Act ,Quarterly Report ,Vice President ,Investor Relations ,Markets ,